Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life.

Abstract

Half of severely asthmatic adolescents treated with omalizumab transitioning to adulthood discontinue the treatment, suggesting insufficient asthma control. However, most of the other half have low rates of HCRU markers, their asthma being under control. https://bit.ly/49ixpxt.